PDCD1 and lung carcinoma: Furthermore, with the United States Food and Drug Administration (U.S. FDA) approval of immune checkpoint inhibitor (ICI) therapy targeting programmed cell-death protein 1 (PD-1) or its ligand 1 (PD-L1) in 2015, there has been further improvement in lung cancer-specific survival [6,7].